Adaptive Total Debt To Capitalization from 2010 to 2024
| ADPT Stock | USD 2.91 0.10 3.32% |
Total Debt To Capitalization | First Reported 2010-12-31 | Previous Quarter 0.31228941 | Current Value 0.33 | Quarterly Volatility 0.09350104 |
Check Adaptive Biotechnologies financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Adaptive main balance sheet or income statement drivers, such as Interest Income of 14.2 M, Discontinued Operations of 0.0 or Depreciation And Amortization of 23.3 M, as well as many exotic indicators such as Price To Sales Ratio of 3.95, Dividend Yield of 0.0 or PTB Ratio of 2.41. Adaptive financial statements analysis is a perfect complement when working with Adaptive Biotechnologies Valuation or Volatility modules.
Adaptive | Total Debt To Capitalization |
Latest Adaptive Biotechnologies' Total Debt To Capitalization Growth Pattern
Below is the plot of the Total Debt To Capitalization of Adaptive Biotechnologies Corp over the last few years. It is Adaptive Biotechnologies' Total Debt To Capitalization historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Adaptive Biotechnologies' overall financial position and show how it may be relating to other accounts over time.
| Total Debt To Capitalization | 10 Years Trend |
|
Total Debt To Capitalization |
| Timeline |
Adaptive Total Debt To Capitalization Regression Statistics
| Arithmetic Mean | 0.11 | |
| Geometric Mean | 0.09 | |
| Coefficient Of Variation | 81.72 | |
| Mean Deviation | 0.07 | |
| Median | 0.06 | |
| Standard Deviation | 0.09 | |
| Sample Variance | 0.01 | |
| Range | 0.2698 | |
| R-Value | 0.79 | |
| Mean Square Error | 0 | |
| R-Squared | 0.62 | |
| Significance | 0.0005 | |
| Slope | 0.02 | |
| Total Sum of Squares | 0.12 |
Adaptive Total Debt To Capitalization History
About Adaptive Biotechnologies Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include Adaptive Biotechnologies income statement, its balance sheet, and the statement of cash flows. Adaptive Biotechnologies investors use historical funamental indicators, such as Adaptive Biotechnologies's Total Debt To Capitalization, to determine how well the company is positioned to perform in the future. Although Adaptive Biotechnologies investors may use each financial statement separately, they are all related. The changes in Adaptive Biotechnologies's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Adaptive Biotechnologies's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Adaptive Biotechnologies Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Adaptive Biotechnologies. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Total Debt To Capitalization | 0.31 | 0.33 |
Pair Trading with Adaptive Biotechnologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Adaptive Biotechnologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adaptive Biotechnologies will appreciate offsetting losses from the drop in the long position's value.Moving together with Adaptive Stock
| 0.77 | VRTX | Vertex Pharmaceuticals Financial Report 6th of May 2024 | PairCorr |
Moving against Adaptive Stock
| 0.74 | ERNA | Eterna Therapeutics | PairCorr |
| 0.73 | A | Agilent Technologies Financial Report 28th of May 2024 | PairCorr |
| 0.73 | DSGN | Design Therapeutics Financial Report 14th of May 2024 | PairCorr |
| 0.68 | NVO | Novo Nordisk AS Financial Report 2nd of May 2024 | PairCorr |
| 0.62 | LLY | Eli Lilly Sell-off Trend | PairCorr |
The ability to find closely correlated positions to Adaptive Biotechnologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Adaptive Biotechnologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Adaptive Biotechnologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Adaptive Biotechnologies Corp to buy it.
The correlation of Adaptive Biotechnologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Adaptive Biotechnologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Adaptive Biotechnologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Adaptive Biotechnologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Adaptive Biotechnologies Correlation against competitors. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Complementary Tools for Adaptive Stock analysis
When running Adaptive Biotechnologies' price analysis, check to measure Adaptive Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Adaptive Biotechnologies is operating at the current time. Most of Adaptive Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Adaptive Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Adaptive Biotechnologies' price. Additionally, you may evaluate how the addition of Adaptive Biotechnologies to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal |
Is Adaptive Biotechnologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Adaptive Biotechnologies. If investors know Adaptive will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Adaptive Biotechnologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.56) | Revenue Per Share 1.179 | Quarterly Revenue Growth (0.17) | Return On Assets (0.17) | Return On Equity (0.58) |
The market value of Adaptive Biotechnologies is measured differently than its book value, which is the value of Adaptive that is recorded on the company's balance sheet. Investors also form their own opinion of Adaptive Biotechnologies' value that differs from its market value or its book value, called intrinsic value, which is Adaptive Biotechnologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Adaptive Biotechnologies' market value can be influenced by many factors that don't directly affect Adaptive Biotechnologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Adaptive Biotechnologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Adaptive Biotechnologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Adaptive Biotechnologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.